Jeffrey Crawford, M.D. is
the DSMB Chairman for Study 105 and Study 106.
Crawford is a Professor
of Medicine at Duke University. He is
of NCCN guidelines for neutropenia management in the U.S. and was the lead
investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF,
Neupogen), which received approval from Food and Drug Administration in 1991.